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Abstract
Desmoid tumor (also called aggressive fibromatosis) is a lesion of mesenchymal origin that can occur as a sporadic
tumor or a manifestation of the preneoplastic syndrome, familial adenomatous polyposis caused by a mutation in
adenomatous polyposis coli (APC). This tumor type is characterized by the stabilization of β-catenin and activation
of Tcf-mediated transcription. Cell transplantation data suggest that desmoid tumors are derived from mesenchymal
progenitor cells (MSCs). As such, modulating cell signaling pathways that regulateMSC differentiation or proliferation,
such as hedgehog (Hh) signaling, could alter the tumor phenotype. Here, we found that Hh signaling is activated in
human and murine desmoid tumors. Inhibiting Hh signaling in human cell cultures decreased cell proliferation and
β-catenin protein levels. Apc+/Apc1638N mice, which develop desmoid tumors, develop smaller and fewer tumors
when Hh signaling was inhibited either genetically (by crossing Apc+/Apc1638N mice with mice lacking one copy of
a Hh-activated transcription factor, Gli2+/−mice) or using a pharmacologic inhibitor. Both in mice and in human tumor
cell cultures, β-catenin and Hh-mediated signaling positively regulate each other’s activity. These data show that
targeting a pathway that regulates MSC differentiation influences desmoid tumor behavior, providing functional
evidence supporting the notion that these tumors are derived from mesenchymal progenitors. It also suggests
Hh blockade as a therapeutic approach for this tumor type.
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Introduction
Desmoid tumor, also called aggressive fibromatosis, is a locally invasive
soft tissue tumor composed of a monoclonal proliferation of mesen-
chymal cells [1]. Although these lesions do not metastasize to distant
sites, morbidity and mortality result from the local effects on vital
organs [2,3]. They can occur either as a sporadic lesion or as part of
familial adenomatous polyposis [4]. Patients with familial adenomatous
polyposis have a 1000-fold increased risk of developing aggressive
fibromatoses, compared with the general population [5]. In sporadic
cases, tumors are associated with somatic mutations in either β-catenin
coding gene (CTNNB1) or adenomatous polyposis coli (APC ) gene,
whereas in familial adenomatous polyposis, tumors contain germline
mutations in APC gene [6,7]. In both cases, the genetic alterations
cause stabilization of β-catenin and activation of β-catenin–mediated
T cell factor–dependent transcriptional activity [8]. Consistent with
this, overexpressing a stabilized form of β-catenin is sufficient to cause
desmoid tumors in mice [9]. Apc1638N mice that harbor a targeted
mutation in the APC gene develop aggressive fibromatoses at a high
frequency [10,11].
β-Catenin is a key signaling molecule in the canonical Wnt signaling
pathway. In the absence of activatingWnt ligands, a complex of proteins
including APC, axin, and glycogen synthase kinase 3-β phosphorylates
and targets the β-catenin for ubiquitin-dependent degradation. When
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an activating Wnt ligand is present, it binds to the Frizzled receptor
and low-density lipoprotein (LDL) receptor–related protein 5/6 co-
receptors. This binding destabilizes themultiprotein complex. As a result,
the unphosphorylated β-catenin accumulates in the cytoplasm and
translocates into the nucleus where it binds to transcription factors in
the T cell factor/lymphoid enhancer-binding factor (LEF) family to
activate transcription and expression of target genes [12,13].
The hedgehog (Hh) signaling pathway plays central roles in the
development and maintenance of normal cells, and its aberrant activa-
tion is associated with several cancer types [14]. An Hh protein will
bind to the Patched-1 (Ptch1) receptor, which in turn relieves its in-
hibition on another transmembrane protein Smoothened (Smo). The
ultimate target of Smo action in mammals is the glioma-associated
(Gli) family of zinc-finger transcription factors that mediate signal
transduction to the nucleus and activate the expression of the pathway
target genes such asGLI1, PTCH1, andHHIP [15]. Three Gli proteins
are identified in vertebrates. Gli3 is phosphorylated into Hh signaling
into a repressor or activator form. Gli1 and Gli3 have been shown to
exist only in an activator form in vivo [16–18].
Studies in mice suggest that desmoid tumor derives from mesen-
chymal progenitor cells (MSCs). Desmoid tumors show a gene expres-
sion profile similar to that seen in MSCs, and driving an oncogenic
mutation stabilizing β-catenin in bone marrow–derived MSCs, but
not in differentiated fibroblasts, will cause tumors when transplanted
into immunodeficient mice [19,20]. This raises the possibility that
signaling pathways that maintain MSCs in a less differentiated state also
play a similar role in desmoid tumor cells. One such signaling path-
way is the Hh pathway, which maintains MSCs in a less differentiated
state with more proliferative capacity [21–23]. The Wnt/β-catenin
and Hh signaling pathways frequently interact with each other during
development and in select tumor types [24–32], raising the possibil-
ity that a similar interaction could be occurring in desmoid tumors.
Pharmacological agents that block Hh signaling are in clinical use [33],
and as such, Hh inhibition could be a novel therapeutic approach for
this tumor type. In this study, we examined the role of Hh signaling
pathway in desmoid tumorigenesis.
Materials and Methods
Human Tumor Samples
Primary human desmoid tumors were obtained at the time of
surgery. Tumor tissue and surrounding normal fibrous tissue were
harvested and processed immediately following the surgical excision.
Tissues were cryopreserved and stored for future use. Cells were also
collected from tumors immediately after surgery to establish primary
cell cultures, using previously reported techniques [34].
Genetically Modified Mice
Apc+/1638N mice harbor a targeted chain-termination mutation at
codon 1638 of the APC gene in one allele [10]. Male mice develop
an average of 45 fibromatoses by 6 months of age. Females develop
a smaller number of tumors than the male mice, due to the effect of
testosterone [11,35]. Gli−/− mice, also called Gli2 zfd (zinc-finger dele-
tion) mice, have a deletion in a 2.4-kb region of Gli2 resulting in the
inability to transactivate transcription [16,36]. Homozygous mutants
are embryonic lethal, while heterozygous mutants are viable but demon-
strate a decrease in Hh-mediated transcriptional activity. Catnblox(ex3)
mice contain loxP sites flanking exon 3 [37]. When subjected to Cre
recombinase, this results in the expression of a functional β-catenin
protein missing the N-terminal phosphorylation sites and, as such, is a
constitutively stabilized and transcriptionally active protein.
Inhibition of Hh Signaling In Vivo
Fourteen 6-week-old Apc+/1638N male mice were treated using oral
gavage with triparanol (C27H32ClNO2; Hoechst Marion Roussel,
Cincinnati, OH), three times a week at a dose of 400 mg/kg. Tri-
paranol is an Hh inhibitor but also has anticholesterol properties
[38,39]. Fifteen control mice receiving carrier (olive oil) were used as
controls. They were treated until they were 6 months of age, after
which they were sacrificed and examined for tumor formation, as
previously reported by an observer blinded to the treatments [11].
Tumors and normal tissues were harvested for RNA and protein
extraction. Because triparanol inhibits cholesterol biosynthesis and
thus reduces serum cholesterol [38,40], this was measured to deter-
mine if the mice were able to absorb the drug using the Amplex
red cholesterol assay (Invitrogen, Cambridge, MA) [41]. To deter-
mine whether triparanol treatment inhibited Hh signaling in vivo,
the level of expression of Hh pathway target gene, Ptch1, was measured
in tissues from treated and control mice by real-time polymerase chain
reaction (PCR).
Mice lacking Gli2 show a similar phenotype to that of seen in mice
lacking Hh ligands, and Gli2 has not been shown to be processed to an
inhibitor form in vivo [42]. We crossed Gli2+/− mice with Apc+/1638N
mice, using a previously described strategy [43] to generate Apc+/1638N;
Gli2+/− and Apc+/1638N;Gli2+/+ littermates. Ten Apc+/1638N;Gli2+/−
and 14 Apc+/1638N;Gli2+/+ male mice were analyzed and sacrificed at
6 months of age, and the number and volume of tumors formed were
scored [11,43].
Cell Culture Studies
Primary cell cultures from human desmoid tumors were main-
tained as previously described [34]. To treat the desmoid cells in vitro,
cell culture experiments were performed in low serum (1%) media
containing 5 μM triparanol diluted in DMSO to inhibit Hh signaling,
and the same concentration of DMSO was used as a carrier control.
Cells were studied for the effect of Hh inhibition after 48 hours of
incubation. To determine whether our treatment inhibited Hh signal-
ing in cultured cells, the level of expression of the pathway target gene,
GLI1, was measured in treated and untreated cells. To examine the
level of β-catenin protein after the treatment, the cell lysates were
extracted from treated and untreated cells. Apoptosis was measured
using the Caspase-Glo 3/7 Assay according to the manufacturer’s instruc-
tion (Promega, Madison, WI) [44]. For proliferation assays, cells were
treated for 12 hours with bromodeoxyuridine (BrdU), fixed, and stained
for immunohistochemistry. The percent positively stained cells was
calculated by counting cells over 10 high-powered fields.
Primary dermal fibroblast cultures from mice expressing the stabi-
lized allele of β-catenin, Catnblox(ex3), were established as reported
[34]. Cells were treated either with adenovirus expressing Cre recom-
binase and green fluorescent protein (GFP) as a marker or with an
adenovirus expressing only GFP with an multiplicity of infection
(MOI) of 230 virus particles per cell (Vector Biolabs, Philadelphia,
PA). After 48 hours of incubation, cells were observed under the fluo-
rescent microscope to verify successful infection. Cells were examined
for β-catenin protein level using Western blot analysis [37]. RNA was
also isolated for gene expression studies.
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RNA Analysis and Western Blot Analysis
Total RNA was isolated from human tissue samples, murine tissues,
and human and murine cell cultures using TRIzol reagents. Equal
amount of RNA was used to generate single-strand cDNA using reverse
transcription. Quantitative real-time PCRwas performed using TaqMan
primers for humanGLI1, PTCH1, andGAPDH and murineGli1,Gli2,
Ptch1, Hhip, and Actin (Applied Biosystems, Grand Island, NY). The
threshold cycle, C t, was determined using the analysis software SDS2.1.
The ΔΔC t method was used for the analysis of the data [45].
Western blot analysis was performed to determine protein expression.
Equal amounts of total protein were separated by electrophoresis using
sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Nitro-
cellulose membranes (Amersham, Salt Lake City, UT) were probed
with an antibody against protein of interest. Polyclonal goat anti-GLI1
(AF3324; R&D Systems, Minneapolis, MN), monoclonal mouse
anti–β-catenin (610154; BD Biosciences, Franklin Lakes, NJ), and
monoclonal mouse anti-actin (Calbiochem, Billerica, MA) were used as
the primary labeling antibodies. Target protein bands were detected using
appropriate HRP-conjugated secondary antibodies (BD Biosciences) and
the enhanced chemiluminescence detection system (WBLUR0100 and
WBLUF0100;Millipore, Billerica, MA) according to the manufacturer’s
instruction. Densitometry was performed using the ImageJ software
(National Institutes of Health, Bethesda, MD).
To isolate the nuclei from cell culture, a process of freezing, thaw-
ing, and lysing is reported by Wood and Earnshaw [46]. Western blot
analysis for β-catenin, actin, and histone was performed on the cyto-
plasmic and nuclear fractions as previously reported. The β-catenin
protein levels in the cytoplasmic or nuclear fraction were compared
between cultures by normalizing the β-catenin level to tubulin or
nuclear histone protein level [47].
Fibroblastic CFU Assay
The femurs and tibias of 4-month-old male Apc+/1638N;Gli2+/− and
Apc+/1638N;Gli2+/+ (littermates) mice were harvested for bone marrow
isolation to measure CFU as previously reported [48]. Cells (1.9 × 106)
were seeded in triplicate in 12-well cell culture plates and grown for
8 days in alpha modification of Eagle’s medium with high glucose
supplement, glutamine, 10% FBS, and 1× antibiotic/antimycotic. After
96 hours, the medium was changed to remove nonadherent cells. After
8 days, cells were stained with 0.25% crystal violet solution (C3886;
Figure 1. Hh signaling is activated in desmoid tumors. (A) Relative level of expression of Hh target genes, GLI1, PTCH1, and HHIP, in
human desmoid tumors and adjacent normal fascia tissue from the same patients. (B) Relative level of expression of Gli1, Gli2, and
Ptch1 in mouse tumors and adjacent normal tissue. Data are given as means and 95% confidence intervals. An asterisk above the
desmoid tumor data indicates a statistically significant difference from normal tissues (P < .05). (C) Representative Western blot from
a mouse tumor and adjacent normal tissue showing higher level of Gli1 and Gl2 and lower level of the repressor form of Gli3 in the tumor
cells. (D) Gli1 immunostaining from a human tumor, showing Gli1 protein expression in many of the cells, with expression localized to
the nucleus. A representative Western blot analysis for Gli1 is also shown from a human tumor and adjacent normal tissues on the right
top panel, and an isotype control immunostaining histologic section is shown on the right lower panel.
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Sigma, St Louis, MO) and the number of colonies >50 cells was
counted by an observer blinded to the genotypes [49].
Statistical Analysis
Means, SDs, and 95% confidence intervals were calculated for each
experiment. Student’s t test was used to compare means between
different experimental conditions.
Results
Hh Signaling Pathway Is Activated in Human and Murine
Desmoid Tumors
The level of expression of Hh target genes, GLI1, PTCH1, and
HHIP, was compared between human desmoid tumors and adjacent
normal tissues from the same patients. These target genes were signif-
icantly upregulated in the desmoid tumor tissues compared to adjacent
normal fascia (Figure 1A). Murine desmoid tumor and adjacent normal
tissues were examined using real-time PCR for the expression of Gli1,
Ptch1, and Hhip, and similar to the situation in the human tumors,
the expression of these target genes were also significantly upregulated
in the tumors (Figure 1B). Because we planned to delete one copy of
Gli2 in the tumors to inhibit Hh signaling, we also examined the ex-
pression of Gli2 in the mice and found that this was also upregulated
compared to normal tissues (P < .05, Figure 1B).We usedWestern blot
analysis to investigate the level of expression of the three GLI proteins in
desmoid tumors and adjacent normal tissues. The level of expression of
Gli1 and Gli2 was 2.1 and 2.6 times higher in tumor tissues than
adjacent normal tissues (95% confidence levels, 0.45 and 0.57, respec-
tively; differences are significant in both cases, P < .01; Figure 1C). Gli3
is processed into a repressor and activator form. In tumor tissues, there
was a significantly lower protein level of the repressor form (0.6 times
lower in tumor tissue, P < .01). Immunostaining revealed the presence
of positive cytoplasmic and nuclear staining in many of the tumor
cells (Figure 1D). These data show that the Hh signaling pathway is
activated in desmoid tumors.
Hh Pathway Inhibition Results in a Reduction in the
Number and Volume of Desmoid Tumors In Vivo
Since Hh target genes were upregulated in both human and murine
aggressive fibromatoses, we investigated the role of Hh signaling in
Figure 2. Hh pathway inhibition results in a decrease in tumor number and size. (A) Desmoid tumors in triparanol-treated mice showed a
smaller volume than in control mice. (B) The Amplex red cholesterol assay showed that the serum cholesterol of mice treated with
triparanol was half of that of mice treated with the carrier, indicating that the mice were able to absorb triparanol. (C) Treatment with
triparanol resulted in a decreased level of expression of Ptch1 in mouse desmoid tumors. (D) The number of tumors in Apc+/Apc1638N;
Gli2zfd/+ mice was decreased when compared to their littermate controls. (E) The level of expression of the Hh target gene, Ptch1, in
tumors from mice lacking one copy of Gli2 is lower than in tumors from control littermate mice. Data are given as means and 95%
confidence intervals. An asterisk above the data bar indicates a statistically significant difference from controls (P < .05).
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this tumor type in vivo. First, to examine whether the pharmacologic
modulation of Hh signaling might alter the tumor phenotype, we
used Apc+/1638N mice with the Hh inhibitor, triparanol, or the carrier,
olive oil, as a control. Tumors in triparanol-treated mice showed a
volume that was 30% smaller than control mice (P < .01, Figure 2A).
We did not observe a significant difference between the numbers of
tumors between the two study groups, likely because the treatment
was started after tumors had already formed. The Amplex red choles-
terol assay showed that the serum cholesterol of mice treated with tri-
paranol was half of that of mice treated with the carrier, indicating that
the mice were able to absorb triparanol (P < .01, Figure 2B). To con-
firm that treatment with triparanol inhibited Hh signaling in mice, the
level of expression of Ptch1 was measured in the tumors and normal
tissues by real-time PCR. Ptch1 expression was decreased significantly
in the triparanol-treated tissues compared to the control tissues (P <
.05, Figure 2C).
To genetically inhibit Hh signaling in desmoid tumors, we crossed
Gli2+/− mice with Apc+/1638N mice. At 6 months of age, mice were
sacrificed and the number and volume of tumors that formed were
scored. The number of tumors in Apc+/1638N;Gli2+/− mice was de-
creased by 38% when compared to their littermate controls (P < .01,
Figure 2D). There was a 20% decrease in tumor volumes between
the two groups. To confirm that the genetic alteration of Gli2 down-
regulated Hh signaling in the crosses, the level of expression of Ptch1
was measured in the tumors that formed in the two groups by real-time
PCR, and this showed a significant decreased in Apc+/1638N;Gli2+/−
mice compared to their littermate Gli2+/+ control (P < .05, Figure 2E).
Taken together, this shows that Hh inhibition in vivo regulates both
the number and size of desmoid tumors in the mice.
Hh Signaling Regulates Cell Proliferation and the Number
of Mesenchymal Progenitors
Because Hh signaling inhibition leads to a decrease in proliferation
and clonogenicity of MSCs [21], we tested if we could see evidence
of this in our mice. The number of fibroblastic CFU (CFU-F; a sur-
rogate measure of MSCs present in the bone marrow) was compared
between Apc+/1638N;Gli2+/− mice and Apc+/1638N;Gli2+/+ littermates.
There was a significant reduction in the numbers of CFU-F in
4-month-old Apc+/1638N;Gli2+/− compared with Apc+/1638N;Gli2+/+ litter-
mates (P < .05, Figure 3A). To explore how Hh regulates cell viability,
proliferation, and apoptosis, we examined primary cell cultures from
human tumors. Cells were examined for viability, proliferation, and
apoptosis rates after 48 hours of incubation with 5 μM triparanol.
The expression of GLI1 was significantly downregulated following tri-
paranol treatment. Treatment inhibited the number of tumor cells, as
measured by viability using the CellTiter96 reagent (P < .05, Figure 3B).
There was a 30% decrease in proliferation rate, as measured by BrdU
incorporation (Figure 3C). However, there was no significant difference
in apoptosis, as measured using caspase-3/7 activity.
Hh Regulates β-Catenin Level and β-Catenin Regulates
Hh Activity
Because it is known that Hh signaling and β-catenin signaling can
regulate each other’s activity, we analyzed if this was the case in des-
moids. To investigate if β-catenin protein level was modulated by
Hh in vitro, we examined the level of β-catenin and its subcellular
localization in primary cell cultures from human tumors. Western blot
analysis using an antibody against total β-catenin protein revealed a
reduction in the amount of total protein, as well as nuclear protein,
in the triparanol-treated cells compared to the vehicle-treated cells
(P < .001, Figure 4A). We then examined tumors from Apc1638N and
Gli2zdf/+ crosses and found a reduction in β-catenin protein level after
Hh inhibition in vivo (Figure 4B). To determine if β-catenin–mediated
signaling could regulate Hh signaling, the expression of Hh pathway
target genes, Gli1, Ptch1, and Hhip, was examined in the primary der-
mal fibroblast cultures derived from mice expressing the conditional
stabilized β-catenin allele (Figure 4, C–E). Real-time PCR showed an
up-regulation in Gli1, Ptch1, and Hhip expression levels in cells expres-
sing stabilized β-catenin but not in the control cells (P < .01, P < .05, and
P < .01, respectively; Figure 4E). Thus, the Hh and β-catenin signaling
pathways regulate each other in desmoid tumors and in fibroblasts.
Discussion
Here, we showed that Hh signaling is active in both human and mouse
desmoid tumors. Mice predisposed to desmoid tumor formation de-
veloped fewer and smaller tumors when the Hh pathway was inhibited.
Figure 3. Hh regulates tumor cell proliferation and the number of
mesenchymal progenitors in the bone marrow. (A) There was a sig-
nificant reduction in the numbers of CFU-F in 4-month-old Apc+/
Apc1638N;Gli2+/− compared with Apc+/Apc1638N;Gli2+/+ litter-
mates. Graph shows means and 95% confidence intervals, and a
representative cell culture dish showing differences in CFU-F is
shown in B. (C) Triparanol treatment inhibited tumor cell viability in
human tumors, as measured using the CellTiter96 reagent. (D) Tri-
paranol treatment inhibited BrdU incorporation in human tumor cell
cultures. Data are given as means and 95% confidence intervals.
An asterisk above a data bar indicates a statistically significant
difference from controls (P < .05).
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These mice also developed fewer CFU-F compared with their wild-type
littermates, suggesting that Hh inhibition results in a lower number of
MSCs in the mice. Moreover, we found that the Hh and β-catenin
signaling pathways regulate each other in this tumor type. Thus, our
results show that modulation of a signaling pathway known to regu-
late MSCs also regulates the behavior of desmoid tumor cells, thus
revealing a novel role for Hh signaling pathway, or perhaps other
pathways regulating MSC proliferation, self-renewal, or differentiation,
in desmoid tumors.
Hh signaling can regulate cell proliferation or differentiation in neo-
plasia, where it can be activated as a result of a mutation in one of the
pathway components (ligand-independent) or by expression of an Hh
ligand (ligand-dependent) [50]. Drugs that inhibit Hh signaling act on
Smo and, thus, work best when the pathways are activated upstream of
this mediator [51,52]. Here, we showed that Hh signaling is activated
in desmoid tumors, likely through a ligand-dependent mechanism.
Hh signaling maintains adult stem or progenitor cells, including
MSCs, in an undifferentiated state [21,22]. Desmoid tumors most likely
arise from mesenchymal precursor cells [19,20]. As such, signaling path-
ways that regulate mesenchymal precursor cell behavior, such as Hh
pathway, may also regulate cell behavior in this tumor type. Therefore,
inhibiting the Hh pathway could cause the MSC population to attain a
Figure 4. Hh and β-catenin positively regulate each other’s activity in desmoid tumors and fibroblasts. (A) The level of β-catenin, in both
nuclear and cytoplasmic fractions, from primary cell cultures from human tumors is decreased with Hh inhibition. A representative
Western blot and composite data showing differences in the relative densitometric measures of the β-catenin band compared to the
loading control is shown. (B) Similar data from tumors from Apc1638N mice expressing wild-type Gli2 or missing one allele Gli2 showing
a reduction in β-catenin protein level in tumors from mice lacking one copy of Gli2. (C–E) The expression of Hh pathway target genes,
Gli1, Ptch1, and Hhip, was upregulated in primary dermal fibroblast cultures derived from mice expressing a conditional stabilized
β-catenin allele. (C) Immunofluorescence showing that the majority of cells were successfully infected with a virus expressing Cre recom-
binase (as detected by GFP). (D) A representative Western blot showing that cell cultures infected with Cre recombinase expressed a
smaller sized β-catenin band indicative of successful recombination and expression of the stabilized form of the protein lacking exon 3.
(E) Real-time PCR showed an up-regulation in Gli1, Ptch1, and Hhip expression levels in cells expressing stabilized β-catenin but not in the
control cells. Data are given as means and 95% confidence intervals. An asterisk above a data point indicates significant differences from
control conditions (P < .05).
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more differentiated cellular phenotype with a reduced capacity to pro-
liferate and, as a result, could lower the number of cells that have the
potential to become tumors. Consistent with this notion, in our study,
we found that both numbers of CFU-F and tumors formed in mice with
reduced Hh activity were less than that of their wild-type littermates.
Multiple levels of cross talk exist between Wnt and Hh signaling
development and differentiation. For example, in Drosophila, the
F-box protein and β-TrCP homolog, Slimb, regulates the degrada-
tion of Armadillo (β-catenin homolog) and Ci (Gli homolog) [24].
In mammals, Gli proteins regulate the expression of Wnt genes [25],
and Indian hedgehog (IHh) is a negative regulator of Wnt signaling
in the differentiation of colonic epithelial cells [26]. The association
between these two signaling pathways is also reported in cancer. Posi-
tive regulation of the Wnt pathway by Hh signaling is demonstrated
in murine pancreas, skin, and brain tumors [27–29]. However, there
are conflicting results from studies on intestinal tumorigenesis. One
study reported that Smo overexpression contributes to intestinal tumori-
genesis by increasing β-catenin–dependent Wnt signaling [31]. Other
studies show that the Wnt pathway is negatively regulated by Hh
signaling in colon cancer cell lines [26,30]. We found that Hh and
β-catenin–mediated Wnt signaling pathways regulate each other in a
positive feedback loop in desmoid tumors, showing a similar regulation
as in other tumors and developmental processes.
In this study, we used triparanol to inhibit Hh signaling. While
triparanol has off-target effects, as it is an inhibitor of cholesterol bio-
synthesis, it does block Hh signaling pathway upstream of Gli transcrip-
tion factors [40].We started treatment after the tumors arose in the mice,
and this is likely the reason we saw an influence on tumor size but not
tumor number. While it is possible that triparanol had its effect through
an off-target mechanism, our finding showing that mice lacking one
copy of Gli2 also develop fewer tumors suggests that Hh signaling is
indeed responsible for the effect we observed with triparanol treatment.
Here, we identified a similar role for a signaling pathway that regu-
lates MSC differentiation and proliferation in desmoid tumors. This
provides additional support to the notion that desmoid tumors de-
rive from MSCs and suggests that signaling pathways maintaining
mesenchymal progenitors in an undifferentiated state also play the
same role in this tumor type. Our data also raise the possibility that
Hh inhibitors could serve as a novel therapeutic approach to this
tumor type. Since such agents are in development for use in patients,
such an approach can be rapidly translated to patient care.
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